• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1.出血素质与纤溶酶原激活物抑制剂1型第2外显子中的A15T杂合突变相关。
Exp Ther Med. 2010 Jul;1(4):575-577. doi: 10.3892/etm_00000090. Epub 2010 Jul 1.
2
A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide.一例与血浆纤溶酶原激活物抑制剂-1信号肽Ala15Thr突变相关的血浆纤溶酶原激活物抑制剂-1缺乏症病例。
Blood Coagul Fibrinolysis. 2005 Jan;16(1):79-84. doi: 10.1097/00001721-200501000-00013.
3
Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency.4例儿童因先天性纤溶酶原激活物抑制剂-1缺乏所致的出血素质
Haemostasis. 1999;29(5):286-91. doi: 10.1159/000022514.
4
Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.由于1型纤溶酶原激活物抑制剂功能活性降低导致的出血素质
J Clin Invest. 1989 May;83(5):1747-52. doi: 10.1172/JCI114076.
5
Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.人纤溶酶原激活物抑制剂-1(PAI-1)缺乏症:一个PAI-1基因存在无效突变的大家族的特征描述
Blood. 1997 Jul 1;90(1):204-8.
6
Plasminogen activator inhibitor with very long half-life (VLHL PAI-1) can reduce bleeding in PAI-1-deficient patients.半衰期极长的纤溶酶原激活物抑制剂(VLHL PAI-1)可减少PAI-1缺乏患者的出血情况。
Cardiovasc Hematol Disord Drug Targets. 2013 Aug;13(2):144-50. doi: 10.2174/1871529x11313020007.
7
Val17Ile single nucleotide polymorphisms similarly as Ala15Thr could be related to the lower secretory dynamics of PAI-1 secretion: theoretical evidence.Val17Ile 单核苷酸多态性与 Ala15Thr 相似,可能与 PAI-1 分泌的较低分泌动力学有关:理论证据。
Curr Mol Med. 2011 Aug;11(6):512-6. doi: 10.2174/156652411796268678.
8
A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.一种与1型纤溶酶原激活物抑制剂缺乏相关的终身性出血性疾病。
Blood. 1991 Feb 1;77(3):528-32.
9
Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss.全身性或局部应用半衰期延长的纤溶酶原激活物抑制剂(VLHL PAI-1)可减少出血时间和总失血量。
Int J Mol Med. 2010 Oct;26(4):501-4. doi: 10.3892/ijmm_00000491.
10
Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review.纤溶酶原激活物抑制剂-1质量缺陷导致的月经过多:病例报告及文献综述
Clin Appl Thromb Hemost. 2004 Jul;10(3):293-6. doi: 10.1177/107602960401000316.

引用本文的文献

1
Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).蛋白水解作用是恶性肿瘤最基本的特性,其抑制作用可能具有治疗用途(综述)。
Int J Mol Med. 2019 Jan;43(1):15-25. doi: 10.3892/ijmm.2018.3983. Epub 2018 Nov 7.
2
Revisiting Hartert's 1962 Calculation of the Physical Constants of Thrombelastography.重温哈特尔特1962年对血栓弹力图物理常数的计算。
Clin Appl Thromb Hemost. 2017 Apr;23(3):201-210. doi: 10.1177/1076029615606531. Epub 2015 Jan 1.
3
Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.具有极长半衰期的突变型纤溶酶原激活物抑制剂-1与6-氨基己酸的凝块保护活性比较。
Exp Ther Med. 2015 Jun;9(6):2339-2343. doi: 10.3892/etm.2015.2399. Epub 2015 Apr 1.

本文引用的文献

1
Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life.纤溶酶原激活物抑制剂缺陷型小鼠血液中的血栓溶解加速被半衰期非常长的 PAI-1 所抑制。
Pharmacol Rep. 2009 Jul-Aug;61(4):673-80. doi: 10.1016/s1734-1140(09)70119-7.
2
Yin and yang of the plasminogen activator inhibitor.纤溶酶原激活物抑制剂的阴阳学说
Pol Arch Med Wewn. 2009 Jun;119(6):410-7.
3
Plasminogen activator inhibitor type 1 deficiency.纤溶酶原激活物抑制剂1缺乏症
Haemophilia. 2008 Nov;14(6):1255-60. doi: 10.1111/j.1365-2516.2008.01834.x.
4
Studies of whole blood coagulation by oscillatory shear, thromboelastography and free oscillation rheometry.通过振荡剪切、血栓弹力图和自由振荡流变学对全血凝血进行的研究。
Clin Hemorheol Microcirc. 2008;38(4):267-77.
5
Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.高度稳定的1型纤溶酶原激活物抑制剂(VLHL PAI-1)可保护纤维蛋白凝块免受组织纤溶酶原激活物介导的纤维蛋白溶解作用。
Int J Mol Med. 2007 Nov;20(5):683-7.
6
Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.与低纤溶酶原激活物抑制剂1活性相关的高纤维蛋白溶解的实验室证据。
Blood Coagul Fibrinolysis. 2007 Oct;18(7):657-60. doi: 10.1097/MBC.0b013e3282dded21.
7
Urokinase induced fibrinolysis in thromboelastography: a model for studying fibrinolysis and coagulation in whole blood.尿激酶在血栓弹力图中诱导的纤维蛋白溶解:一种研究全血中纤维蛋白溶解和凝血的模型。
J Thromb Haemost. 2005 Nov;3(11):2506-13. doi: 10.1111/j.1538-7836.2005.01615.x.
8
A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide.一例与血浆纤溶酶原激活物抑制剂-1信号肽Ala15Thr突变相关的血浆纤溶酶原激活物抑制剂-1缺乏症病例。
Blood Coagul Fibrinolysis. 2005 Jan;16(1):79-84. doi: 10.1097/00001721-200501000-00013.
9
Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review.纤溶酶原激活物抑制剂-1质量缺陷导致的月经过多:病例报告及文献综述
Clin Appl Thromb Hemost. 2004 Jul;10(3):293-6. doi: 10.1177/107602960401000316.
10
PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population.纤溶酶原激活物抑制剂-1(PAI-1)基因多态性调节肥胖和糖尿病白种人群中与代谢综合征相关的表型。
Diabetologia. 2003 Sep;46(9):1284-90. doi: 10.1007/s00125-003-1170-0. Epub 2003 Jul 11.

出血素质与纤溶酶原激活物抑制剂1型第2外显子中的A15T杂合突变相关。

Bleeding diathesis is associated with an A15T heterozygous mutation in exon 2 of the plasminogen activator inhibitor type 1.

作者信息

Jankun Jerzy, Skrzypczak-Jankun Ewa

机构信息

Urology Research Center, Department of Urology, The University of Toledo - Health Science Campus, 3000 Arlington Ave., Toledo, OH 43614, USA ; ; Department of Clinical Nutrition, Medical University of Gdańsk, Dębinki 7, 80-211 Gdańsk, Poland.

出版信息

Exp Ther Med. 2010 Jul;1(4):575-577. doi: 10.3892/etm_00000090. Epub 2010 Jul 1.

DOI:10.3892/etm_00000090
PMID:22993578
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3445900/
Abstract

In the present study, we present a 60-year-old woman of American Indian descent with a life-long history of bleeding diathesis. She had a history of recurrent and prolonged bleeding such as mild epistaxis, gingival bleeding and microscopic hematurias. She also experienced a severe bleeding event after surgery. The patient had a large family with a history of a tendency of bleeding, severe in some cases. Hemostatic screening studies revealed no abnormalities, which could explain the bleeding tendency. Clot formation of sodium-citrated blood was analyzed by thromboelastography, which suggested a low platelet count or plasminogen activator inhibitor-1 (PAI-1) deficiency. However, her platelet count was slightly elevated. Subsequent sequencing of the PAI-1 gene revealed a heterozygous Ala15Thr mutation in the signal peptide. This type of deficiency is related to dynamics of PAI-1 secretion rather than its low levels or activity. We concluded that the PAI-1 mutation was likely the etiology of the bleeding diathesis in this patient.

摘要

在本研究中,我们报告了一位60岁的美国印第安裔女性,她有终生的出血素质病史。她有反复和长期出血的病史,如轻度鼻出血、牙龈出血和镜下血尿。她在手术后还经历了一次严重的出血事件。该患者家族庞大,有出血倾向的病史,有些病例情况严重。止血筛查研究未发现异常,无法解释其出血倾向。通过血栓弹力图分析枸橼酸钠抗凝血的凝块形成,提示血小板计数低或纤溶酶原激活物抑制剂-1(PAI-1)缺乏。然而,她的血小板计数略有升高。随后对PAI-1基因进行测序,发现在信号肽中有一个杂合的Ala15Thr突变。这种类型的缺乏与PAI-1分泌的动力学有关,而不是其低水平或活性。我们得出结论,PAI-1突变可能是该患者出血素质的病因。